Treatment and prevention of intestinal dysbiosis and associated endogenous dysvitaminosis. Therapy aimed at restoring the normal intestinal microflora, which is disturbed during treatment with antibiotics or chemotherapy drugs. Acute and chronic gastrointestinal diseases associated with intoxication or intestinal dysbiosis and dysvitaminosis in infants who are fed breast milk.
Enterogermina capsules Composition
active substance: 1 capsule contains a mixture of spores of the multidrug-resistant strain of Bacillus clausii 2×109;
Enterogermina capsules excipients: kaolin, microcrystalline cellulose, magnesium stearate;
capsule: gelatin, titanium dioxide (E 171), purified water.
Enterogermina capsules Dosage form
Basic physical and chemical properties: hard white gelatin capsules containing a fine powder from whitish to ivory.
Antidiarrheal microbial drugs. ATX code A07FA.
Enterojermina® is a suspension of Bacillus clausii spores, which are usually present in the intestine and do not show pathogenic activity.
Thanks to the action of Bacillus clausii, the drug restores the intestinal microflora, altered as a result of treatment with drugs leading to dysbiosis. In addition, due to the ability of Bacillus clausii to synthesize various vitamins, especially of group B, the drug helps to correct dysvitaminosis caused by the use of antibiotics or chemotherapy drugs. Due to the metabolic activity of Bacillus clausii, the use of the drug makes it possible to achieve a nonspecific antigenic and antitoxic effect.
Due to their high resistance to chemical and physical agents, spores of Bacillus clausii pass intact through the gastric juice barrier into the intestine, where they are converted into metabolically active vegetative cells.
There is no data.
Treatment and prevention of intestinal dysbiosis and associated endogenous dysvitaminosis.
Adjunctive therapy aimed at restoring the normal intestinal microflora, disturbed by treatment with antibiotics or chemotherapy drugs.
Hypersensitivity to the active substance or any of the excipients.
Children under 5 years of age.
Special security measures
The drug has a high degree of heterologous resistance to antibiotics, which makes it possible to use it both for the prevention of changes in the intestinal microflora caused by the selective action of antibiotics (especially broad-spectrum antibiotics) and for the restoration of an already disturbed balance of the intestinal microflora.
The drug does not interact with such antibiotics: penicillin, cephalosporins, tetracyclines, macrolides, aminoglycosides, novobiocin, chloramphenicol, thiamphenicol, lincomycin, isoniazid, cycloserine, rifampicin, nalidixic acid and pipemidic acid.
If the drug is given concurrently with antibiotics, it should be used between two antibiotic doses.
This medicinal product is intended for oral use only. It is forbidden to inject the drug by injection or any other method. Inappropriate use of this drug has resulted in severe anaphylactic reactions such as anaphylactic shock.